178 related articles for article (PubMed ID: 24524281)
1. Estimating the budget impact of orphan drugs in Sweden and France 2013-2020.
Hutchings A; Schey C; Dutton R; Achana F; Antonov K
Orphanet J Rare Dis; 2014 Feb; 9():22. PubMed ID: 24524281
[TBL] [Abstract][Full Text] [Related]
2. Estimating the budget impact of orphan medicines in Europe: 2010 - 2020.
Schey C; Milanova T; Hutchings A
Orphanet J Rare Dis; 2011 Sep; 6():62. PubMed ID: 21951518
[TBL] [Abstract][Full Text] [Related]
3. An analysis of orphan medicine expenditure in Europe: is it sustainable?
Mestre-Ferrandiz J; Palaska C; Kelly T; Hutchings A; Parnaby A
Orphanet J Rare Dis; 2019 Dec; 14(1):287. PubMed ID: 31829218
[TBL] [Abstract][Full Text] [Related]
4. The European challenges of funding orphan medicinal products.
Szegedi M; Zelei T; Arickx F; Bucsics A; Cohn-Zanchetta E; Fürst J; Kamusheva M; Kawalec P; Petrova G; Slaby J; Stawowczyk E; Vocelka M; Zechmeister-Koss I; Kaló Z; Molnár MJ
Orphanet J Rare Dis; 2018 Nov; 13(1):184. PubMed ID: 30396361
[TBL] [Abstract][Full Text] [Related]
5. Novel methodology for pharmaceutical expenditure forecast.
Vataire AL; Cetinsoy L; Aballéa S; Rémuzat C; Urbinati D; Kornfeld Å; Mzoughi O; Toumi M
J Mark Access Health Policy; 2014; 2():. PubMed ID: 27226843
[TBL] [Abstract][Full Text] [Related]
6. Impact of orphan drugs on Latvian budget.
Logviss K; Krievins D; Purvina S
Orphanet J Rare Dis; 2016 May; 11(1):59. PubMed ID: 27169704
[TBL] [Abstract][Full Text] [Related]
7. Costs of orphan medicinal products: longitudinal analysis of expenditure in Wales.
Pijeira Perez Y; Wood E; Hughes DA
Orphanet J Rare Dis; 2023 Nov; 18(1):342. PubMed ID: 37915031
[TBL] [Abstract][Full Text] [Related]
8. Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU.
Joppi R; Bertele' V; Garattini S
Eur J Clin Pharmacol; 2013 Apr; 69(4):1009-24. PubMed ID: 23090701
[TBL] [Abstract][Full Text] [Related]
9. Pharmaceutical expenditure on drugs for rare diseases in Canada: a historical (2007-13) and prospective (2014-18) MIDAS sales data analysis.
Divino V; DeKoven M; Kleinrock M; Wade RL; Kim T; Kaura S
Orphanet J Rare Dis; 2016 May; 11(1):68. PubMed ID: 27207271
[TBL] [Abstract][Full Text] [Related]
10. Budgetary Impact and Cost Drivers of Drugs for Rare and Ultrarare Diseases.
Schlander M; Dintsios CM; Gandjour A
Value Health; 2018 May; 21(5):525-531. PubMed ID: 29753348
[TBL] [Abstract][Full Text] [Related]
11. A systematic review of moral reasons on orphan drug reimbursement.
Zimmermann BM; Eichinger J; Baumgartner MR
Orphanet J Rare Dis; 2021 Jun; 16(1):292. PubMed ID: 34193232
[TBL] [Abstract][Full Text] [Related]
12. Orphan Medicinal Products for the Treatment of Pancreatic Cancer: Lessons Learned From Two Decades of Orphan Designation.
Mulder J; van Rossum T; Mariz S; Magrelli A; de Boer A; Pasmooij AMG; Stoyanova-Beninska V
Front Oncol; 2021; 11():809035. PubMed ID: 34988030
[TBL] [Abstract][Full Text] [Related]
13. Orphan drugs expenditure in the Netherlands in the period 2006-2012.
Kanters TA; Steenhoek A; Hakkaart L
Orphanet J Rare Dis; 2014 Oct; 9():154. PubMed ID: 25304026
[TBL] [Abstract][Full Text] [Related]
14. Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries.
Morel T; Arickx F; Befrits G; Siviero P; van der Meijden C; Xoxi E; Simoens S
Orphanet J Rare Dis; 2013 Dec; 8():198. PubMed ID: 24365263
[TBL] [Abstract][Full Text] [Related]
15. Patient Accessibility and Budget Impact of Orphan Drugs in South Korea: Long-Term and Real-World Data Analysis (2007-2019).
Lee SH; Yoo SL; Bang JS; Lee JH
Int J Environ Res Public Health; 2020 Apr; 17(9):. PubMed ID: 32357397
[TBL] [Abstract][Full Text] [Related]
16. Comparing access to orphan medicinal products in Europe.
Zamora B; Maignen F; O'Neill P; Mestre-Ferrandiz J; Garau M
Orphanet J Rare Dis; 2019 May; 14(1):95. PubMed ID: 31053154
[TBL] [Abstract][Full Text] [Related]
17. Principles for consistent value assessment and sustainable funding of orphan drugs in Europe.
Gutierrez L; Patris J; Hutchings A; Cowell W
Orphanet J Rare Dis; 2015 May; 10():53. PubMed ID: 25935555
[TBL] [Abstract][Full Text] [Related]
18. Budget impact analysis of drugs for ultra-orphan non-oncological diseases in Europe.
Schlander M; Adarkwah CC; Gandjour A
Expert Rev Pharmacoecon Outcomes Res; 2015 Feb; 15(1):171-9. PubMed ID: 25312018
[TBL] [Abstract][Full Text] [Related]
19. Prices of Orphan Drugs in Four Western European Countries Before and After Market Exclusivity Expiry: A Cross-Country Comparison of List Prices and Purchase Prices.
Dane A; Klein Gebbink AS; Brugma JD; Degrassat-Théas A; Hug MJ; Houlind MB; Paubel P; van der Kuy PHM; Uyl-de Groot CA
Appl Health Econ Health Policy; 2023 Nov; 21(6):905-914. PubMed ID: 37751107
[TBL] [Abstract][Full Text] [Related]
20. EU pharmaceutical expenditure forecast.
Urbinati D; Rémuzat C; Kornfeld Å; Vataire AL; Cetinsoy L; Aballéa S; Mzoughi O; Toumi M
J Mark Access Health Policy; 2014; 2():. PubMed ID: 27226837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
